The Combined Dexamethasone/CRH Test (DEX/CRH Test) and Prediction of Acute Treatment Response in Major Depression

Abstract

BackgroundIn this study the predictive value of the combined dexamethasone/CRH test (DEX/CRH test) for acute antidepressant response was investigated.Methodology/Principal FindingsIn 114 depressed inpatients suffering from unipolar or bipolar depression (sample 1) the DEX/CRH test was performed at admission and shortly before discharge. During their stay in the hospital patients received different antidepressant treatment regimens. At admission, the rate of nonsuppression (basal cortisol levels >75.3 nmol/l) was 24.6% and was not related to the later therapeutic response. Moreover, 45 out of 114 (39.5%) patients showed an enhancement of HPA axis function at discharge in spite of clinical improvement. In a second sample, 40 depressed patients were treated either with reboxetine or mirtazapine for 5 weeks. The DEX/CRH test was performed before, after 1 week, and after 5 weeks of pharmacotherapy. Attenuation of HPA axis activity after 1 week was associated with a more pronounced alleviation of depressive symptoms after 5-week mirtazapine treatment, whereas downregulation of HPA system activity after 5 weeks was related to clinical response to reboxetine. However, early improvement of HPA axis dysregulation was not necessarily followed by a beneficial treatment outcome.Conclusions/SignificanceTaken together, performance of a single DEX/CRH test does not predict the therapeutic response. The best predictor for response seems to be an early attenuation of HPA axis activity within 1 or 2 weeks. However, early improvement of HPA system dysfunction is not a sufficient condition for a favourable response. Since a substantial part of depressive patients display a persistence of HPA axis hyperactivity at discharge, downregulation of HPA system function is not a necessary condition for acute clinical improvement either. Our data underline the importance of HPA axis dysregulation for treatment outcome in major depression, although restoration of HPA system dysfunction seems to be neither a necessary nor a sufficient determinant for acute treatment response.

Luman/CREB3 Recruitment Factor Regulates Glucocorticoid Receptor Activity and Is Essential for Prolactin-Mediated Maternal Instinct

“…There is also a clear link between elevated glucocorticoid signaling, a misregulated HPA axis, and depression (33,43,54). The underlying mechanism, however, is unclear.…”

Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436

“…If AVP has increased influence on HPA axis regulation, then HPA axis activity in MDD and anxiety disorder patients may be particularly sensitive to attenuation by a V 1B antagonist. HPA axis normalization, a potential consequence of V 1B antagonism, has been observed to predict lower relapse risk in remitted MDD patients (Targum 1984) and precede clinical response to antidepressant medications in some patients (Schüle et al 2009). Antagonism of V 1B is thus a mechanism that has potential to address the inadequate therapeutic treatment for MDD and anxiety disorders.…”

Long-Term Outcome after Lithium Augmentation in Unipolar Depression: Focus on HPA System Activity

“…It is generally worth noting that after the initial findings suggesting a correlation of DEX/CRH test findings and clinical course a lack of relationship between the restoration of HPA system dysfunction and acute treatment response has also been reported [37] . Single substances, such as lithium in this study, may also 'break the rules' as has been reported for mirtazapine [38] .…”